Chemed Corporation Declares Quarterly Dividend of $0.60 (NYSE:CHE)

Chemed Corporation (NYSE:CHE) announced a quarterly dividend on Friday, November 7th. Investors of record on Monday, November 17th will be given a dividend of 0.60 per share on Friday, December 5th. This represents a c) dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, November 17th.

Chemed has increased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 16 years. Chemed has a dividend payout ratio of 8.7% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Chemed to earn $23.30 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 10.3%.

Chemed Price Performance

NYSE:CHE traded down $10.83 on Friday, reaching $435.18. The stock had a trading volume of 127,847 shares, compared to its average volume of 153,466. The company has a market cap of $6.16 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 2.69 and a beta of 0.43. Chemed has a 12-month low of $408.42 and a 12-month high of $623.60. The firm’s fifty day moving average is $443.97 and its two-hundred day moving average is $484.16.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing the consensus estimate of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The business had revenue of $624.90 million for the quarter, compared to analysts’ expectations of $626.04 million. During the same quarter last year, the company posted $5.64 earnings per share. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, research analysts forecast that Chemed will post 21.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Patrick P. Grace sold 150 shares of Chemed stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the transaction, the director directly owned 3,397 shares of the company’s stock, valued at $1,574,135.83. This trade represents a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the transaction, the chief executive officer directly owned 96,197 shares of the company’s stock, valued at $44,373,752.16. This represents a 3.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.29% of the stock is owned by insiders.

Institutional Trading of Chemed

Several large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in Chemed by 122.7% during the third quarter. JPMorgan Chase & Co. now owns 499,968 shares of the company’s stock valued at $223,856,000 after buying an additional 275,423 shares in the last quarter. Norges Bank bought a new position in shares of Chemed in the second quarter valued at approximately $89,388,000. AQR Capital Management LLC lifted its stake in shares of Chemed by 160.9% in the second quarter. AQR Capital Management LLC now owns 201,041 shares of the company’s stock worth $97,893,000 after buying an additional 123,982 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Chemed by 69.3% during the 2nd quarter. Acadian Asset Management LLC now owns 250,722 shares of the company’s stock worth $122,056,000 after buying an additional 102,597 shares during the period. Finally, Fuller & Thaler Asset Management Inc. grew its stake in Chemed by 249.3% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 130,037 shares of the company’s stock valued at $80,015,000 after buying an additional 92,813 shares during the last quarter. 95.85% of the stock is owned by institutional investors.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.